UCC December 2020

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

"As we slowly move toward the promise of precision medicine, it is important to understand fully this concept and the importance of testing and how it is to be used for diagnosis, management, and risk assessment," writes Raoul S. Concepcion, MD, FACS.

Recent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.

Research indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.

Improvement in imaging modalities may help in performance of transurethral resection of the bladder tumor.

"If your practice does not closely monitor patients and send them for early salvage radiotherapy when their PSA is 0.1 or 0.2 ng/mL, it is likely that adjuvant radiotherapy is superior," Daniel E. Spratt, MD, writes.